½ÃÀ庸°í¼­
»óǰÄÚµå
1602137

½ºÅÙÆ® ½ÃÀå : À¯Çü, ¼ÒÀç, Àü´Þ ¹æ¹ý, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Stents Market by Type (Coronary Stents, Peripheral Vascular Stents, Prostatic Stents), Material (Biomaterials, Metallic Stents), Mode of Delivery, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ºÅÙÆ® ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 129¾ï 9,000¸¸ ´Þ·¯·Î, 2024³â¿¡´Â 139¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 7.51%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 215¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ºÅÙÆ® ½ÃÀåÀº Á¼¾ÆÁö°Å³ª ¸·Èù Ç÷°üÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â È®Àå °¡´ÉÇÑ ¼ÒÇü Æ©ºê¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÇ·á±â±â »ê¾÷¿¡¼­ Áß¿äÇÑ ºÎ¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â Àü ¼¼°è¿¡¼­ À¯º´·üÀÌ ³ôÀº ½ÉÇ÷°ü ÁúȯÀÇ Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. ½ºÅÙÆ®ÀÇ Çʿ伺Àº Á¤»ó Ç÷·ù¸¦ ȸº¹Çϰí, ½ÉÀ帶ºñ¸¦ ¿¹¹æÇϸç, ÁÖ·Î ÃÖ¼Ò Ä§½ÀÀû ½Ã¼úÀ» ÅëÇØ ÈäÅëÀ» ¿ÏÈ­ÇÏ´Â ´É·Â¿¡¼­ ºñ·ÔµÇ¸ç, ±Þ¼º ¹× ¸¸¼ºÁúȯ ¸ðµÎ¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½ºÅÙÆ®´Â °ü»óµ¿¸Æ, ¸»ÃÊÇ÷°ü, ½Å°æÇ÷°ü µî ´Ù¾çÇÑ ÃÖÁ¾ ¿ëµµ¿¡ Àû¿ëµÇ¸ç, °¢°¢ ƯÁ¤ Ç÷°ü Áúȯ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡, ½ÉÇ÷°ü Áúȯ Áõ°¡, ¾àÁ¦¿ëÃâÇü ½ºÅÙÆ®(DES) ¹× »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå(BVS)¿Í °°Àº Çõ½ÅÀûÀÎ ½ºÅÙÆ® ¼³°è·Î À̾îÁö´Â ±â¼ú ¹ßÀü µîÀÌ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àúħ½ÀÀû ¼ö¼úÀÇ Ã¤Åà Ȯ´ë¿Í Á¤ºÎÀÇ Áö¿øÃ¥ÀÌ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½ºÅÙÆ® Ä¡·áÀÇ ³ôÀº ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ½ºÅÙÆ®³» ÀçÇùÂø ¹× Ç÷ÀüÁõ°ú °°Àº ÀáÀçÀû ÇÕº´Áõ µîÀÇ ¹®Á¦´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾à¿¡µµ ºÒ±¸Çϰí ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÷´Ü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ±¹°¡¿¡¼­´Â ½ÃÀå È®´ëÀÇ ±âȸ°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº Æú¸®¸Ó ÇÁ¸® DES, »ýºÐÇØ¼º DES µî ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ³ôÀÎ ½ºÅÙÆ® °³¹ß¿¡ ´ëÇÑ ¿¬±¸¿Í ±â¼ú Çõ½Å¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» À§ÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í Çù·ÂÇϸé äÅÃÀ» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ Æ¯¼º»ó °æÀïÀÌ Ä¡¿­Çϰí Áö¼ÓÀûÀÎ Çõ½Å¿¡ ´ëÇÑ ¾Ð¹ÚÀÌ ÀÖÀ¸¹Ç·Î ¿¬±¸°³¹ß ¹× Àü·«Àû ÆÄÆ®³Ê½Ê¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ¼ºÀåÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô´Â °³ÀÎÈ­µÈ ½ºÅÙÆ® ¼Ö·ç¼Ç, ´õ ³ªÀº ½ºÅÙÆ® ¹èÄ¡ ¹× ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿µ»ó ±â¼úÀÇ ¹ßÀü µî ÀáÀç·ÂÀÌ Ç³ºÎÇÑ ºÐ¾ß°¡ ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 129¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 139¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 215¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 7.51%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ºÅÙÆ® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

½ºÅÙÆ® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÉÇ÷°ü ÁúȯÀÇ À¯Çà°ú ǰÁú Çâ»ó¿¡ ´ëÇÑ ¿ä±¸ ½ºÅÙÆ®
    • Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
    • »ýºÐÇØ¼º ¹× »ýüÈí¼ö¼º ½ºÅÙÆ®¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ºÅÙÆ® ½Ã½ºÅÛ ¸®ÄÝ ±ÞÁõ
  • ½ÃÀå ±âȸ
    • °íÁ¤¹ÐÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ½ºÅÙÆ® ¼³°èÀÇ »õ·Î¿î ±â¼ú Çõ½Å
    • ±ÔÁ¦ ´ç±¹ÀÇ Á¦Ç° ½ÂÀÎ ±ÞÁõ
  • ½ÃÀå °úÁ¦
    • ½ºÅÙÆ® »ç¿ëÀ¸·Î ÀÎÇÑ À§Çè°ú ±×¿¡ µû¸¥ °Ç°­ ¿µÇâ

Porter's Five Forces: ½ºÅÙÆ® ½ÃÀå °ø·«À» À§ÇÑ Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ºÅÙÆ® ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÏ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½ºÅÙÆ® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½ºÅÙÆ® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ½ºÅÙÆ® ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

½ºÅÙÆ® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½ºÅÙÆ® ½ÃÀå¿¡¼­ÀÇ º¥´õÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½ºÅÙÆ® ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½ºÅÙÆ® ½ÃÀå : À¯Çüº°

  • °ü»óµ¿¸Æ ½ºÅÙÆ®
    • º£¾î¸ÞÅ» ½ºÅÙÆ®
    • ¾àÁ¦¿ëÃâÇü ½ºÅÙÆ®
  • ¸»ÃÊÇ÷°ü ½ºÅÙÆ®
  • Àü¸³¼± ½ºÅÙÆ®
  • ½ºÅÙÆ® ±×¶óÇÁÆ®
  • ´¢½ºÅÙÆ®

Á¦7Àå ½ºÅÙÆ® ½ÃÀå : ¼ÒÀ纰

  • »ýü Àç·á
  • ¸ÞÅ»¸¯ ½ºÅÙÆ®
    • ÄÚ¹ßÆ® Å©·Ò
    • ´ÏÄÌ Æ¼Å¸´½
    • Ç÷¡Æ¼³Ñ Å©·Ò
    • ½ºÅ×Àθ®½º°­

Á¦8Àå ½ºÅÙÆ® ½ÃÀå : Àü´Þ ¹æ¹ýº°

  • dz¼± µµÀÔ °¡´ÉÇÑ ½ºÅÙÆ®
  • ÀÚ±â È®ÀåÇü ½ºÅÙÆ®

Á¦9Àå ½ºÅÙÆ® ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ½ÉÀå ¼¾ÅÍ
  • º´¿ø

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ½ºÅÙÆ® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÁö¿ª½ºÅÙÆ® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ºÅÙÆ® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Alvimedica
  • Mitra Industries Pvt. Ltd.
  • Lepu Medical Technology(Beijing) Co., Ltd.
  • Abbott Laboratories
  • Elixir Medical Corporation
  • Andramed GmbH
  • QMD
  • MicroPort Scientific Corporation
  • Cook Medical LLC
  • Becton, Dickinson and Company
  • Integer Holdings Corporation
  • W. L. Gore & Associates, Inc.
  • SLTL Group
  • Stryker Corporation
  • Arterius Limited
  • Meril Life Sciences Pvt. Ltd.
  • BIOTRONIK SE & Co. KG
  • Eurocor Tech GmbH
  • Nano Therapeutics Pvt. Ltd.
  • Scitech Medical Products SA
  • Balton Sp. z o. o.
  • Cardinal Health Inc.
  • Boston Scientific Corporation
  • KYOTO MEDICAL PLANNING Co., Ltd.
  • Terumo Corporation
  • B. Braun SE
  • REVA Medical, LLC
  • Medtronic PLC
  • Rontis AG
  • Veryan Medical Ltd.
KSA 24.12.10

The Stents Market was valued at USD 12.99 billion in 2023, expected to reach USD 13.95 billion in 2024, and is projected to grow at a CAGR of 7.51%, to USD 21.57 billion by 2030.

The stent market is a vital segment within the medical devices industry, focusing on small, expandable tubes used to treat narrowed or blocked blood vessels. These devices are essential in treating cardiovascular diseases, which have high prevalence worldwide. The necessity for stents arises from their ability to restore normal blood flow, prevent heart attacks, and reduce chest pain, primarily through minimally invasive procedures, making them crucial in both acute and chronic conditions. Stents find application across various end-uses, including coronary, peripheral, and neurovascular placements, each catering to specific vascular disorders. The market is driven by key growth factors such as an increasing elderly population, rising incidences of cardiovascular diseases, and technological advancements leading to innovative stent designs like drug-eluting stents (DES) and bioresorbable vascular scaffolds (BVS). Additionally, the growing adoption of minimally invasive procedures and supportive government initiatives are driving market expansion. However, challenges such as the high cost of stent procedures, stringent regulatory frameworks, and potential complications like in-stent restenosis and thrombosis can impede growth. Despite these limitations, the market presents opportunities in emerging economies where healthcare infrastructure is improving and demand for advanced medical treatments is on the rise. To capitalize on these opportunities, companies should focus on research and innovation in the development of stents that offer enhanced safety and efficacy, such as polymer-free DES and biodegradable stents. Additionally, collaborations with healthcare providers for cost-effective solutions could widen adoption. The market's nature is competitive, with continuous pressure to innovate, demanding a keen focus on R&D and strategic partnerships. For businesses looking to grow, areas rich in potential include personalized stent solutions and advancements in imaging techniques for better placement and monitoring of stents.

KEY MARKET STATISTICS
Base Year [2023] USD 12.99 billion
Estimated Year [2024] USD 13.95 billion
Forecast Year [2030] USD 21.57 billion
CAGR (%) 7.51%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stents Market

The Stents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cardiovascular diseases and need for improved-quality stents
    • Growing inclination toward minimally invasive surgeries
    • Surging preference for biodegradable and bioabsorbable stents
  • Market Restraints
    • Surging incidence of recalls of stent systems
  • Market Opportunities
    • Emerging innovations in stent designs for high accuracy and reliability
    • The surge in product approvals from regulatory authorities
  • Market Challenges
    • Risks of the utilization of stents and associated health consequences

Porter's Five Forces: A Strategic Tool for Navigating the Stents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stents Market

A detailed market share analysis in the Stents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Stents Market, highlighting leading vendors and their innovative profiles. These include Alvimedica, Mitra Industries Pvt. Ltd., Lepu Medical Technology(Beijing)Co., Ltd., Abbott Laboratories, Elixir Medical Corporation, Andramed GmbH, QMD, MicroPort Scientific Corporation, Cook Medical LLC, Becton, Dickinson and Company, Integer Holdings Corporation, W. L. Gore & Associates, Inc., SLTL Group, Stryker Corporation, Arterius Limited, Meril Life Sciences Pvt. Ltd., BIOTRONIK SE & Co. KG, Eurocor Tech GmbH, Nano Therapeutics Pvt. Ltd., Scitech Medical Products SA, Balton Sp. z o. o., Cardinal Health Inc., Boston Scientific Corporation, KYOTO MEDICAL PLANNING Co., Ltd., Terumo Corporation, B. Braun SE, REVA Medical, LLC, Medtronic PLC, Rontis AG, and Veryan Medical Ltd..

Market Segmentation & Coverage

This research report categorizes the Stents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Coronary Stents, Peripheral Vascular Stents, Prostatic Stents, Stent Grafts, and Urinary Stents. The Coronary Stents is further studied across Bare-metal Stents and Drug-eluting Stents.
  • Based on Material, market is studied across Biomaterials and Metallic Stents. The Metallic Stents is further studied across Cobalt-Chromium, Nickel Titanium, Platinum Chromium, and Stainless Steel.
  • Based on Mode of Delivery, market is studied across Balloon-expandable Stents and Self-expanding Stents.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Cardiac Centers, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cardiovascular diseases and need for improved-quality stents
      • 5.1.1.2. Growing inclination toward minimally invasive surgeries
      • 5.1.1.3. Surging preference for biodegradable and bioabsorbable stents
    • 5.1.2. Restraints
      • 5.1.2.1. Surging incidence of recalls of stent systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging innovations in stent designs for high accuracy and reliability
      • 5.1.3.2. The surge in product approvals from regulatory authorities
    • 5.1.4. Challenges
      • 5.1.4.1. Risks of the utilization of stents and associated health consequences
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: High global incidences of coronary diseases necessitating the deployment of coronary stents
    • 5.2.2. End-User: Expansion of hospitals across the world supported by government initiatives for improving healthcare infrastructure
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Stents Market, by Type

  • 6.1. Introduction
  • 6.2. Coronary Stents
    • 6.2.1. Bare-metal Stents
    • 6.2.2. Drug-eluting Stents
  • 6.3. Peripheral Vascular Stents
  • 6.4. Prostatic Stents
  • 6.5. Stent Grafts
  • 6.6. Urinary Stents

7. Stents Market, by Material

  • 7.1. Introduction
  • 7.2. Biomaterials
  • 7.3. Metallic Stents
    • 7.3.1. Cobalt-Chromium
    • 7.3.2. Nickel Titanium
    • 7.3.3. Platinum Chromium
    • 7.3.4. Stainless Steel

8. Stents Market, by Mode of Delivery

  • 8.1. Introduction
  • 8.2. Balloon-expandable Stents
  • 8.3. Self-expanding Stents

9. Stents Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Cardiac Centers
  • 9.4. Hospitals

10. Americas Stents Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Stents Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Stents Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd.
    • 13.3.2. Medtech giant Cordis acquires MedAlliance in a USD 1.1 billion deal.
    • 13.3.3. Getinge partners with Medtronic for the manufacturing of the Radiant[TM] balloon-expandable covered stent.
    • 13.3.4. Medtronic receives CE mark for the first balloon-expandable covered stent indicated for ChEVAR.
    • 13.3.5. Medtronic launches the latest generation drug-eluting coronary stent system following CE Mark approval.
    • 13.3.6. Biosensors International Wins FDA Approval For Drug-Eluting Coronary Stent.
    • 13.3.7. San Diego's Reva Medical raises USD 45 M to develop naturally absorbable stents for lower legs.
    • 13.3.8. Micro-Tech Endoscopy Announces Distribution Partnership with Thoracent to Bring Leading Tracheal Y-Stent System to the U.S. Market.
    • 13.3.9. FDA-Approved FFRangio from CathWorks Receives USD 75 Million Investment from Medtronic with an Option for Eventual Acquisition for Over a Half a Billion.
    • 13.3.10. Abbott launches Xience Skypoint drug-eluting stent in extended sizes.

Companies Mentioned

  • 1. Alvimedica
  • 2. Mitra Industries Pvt. Ltd.
  • 3. Lepu Medical Technology(Beijing)Co., Ltd.
  • 4. Abbott Laboratories
  • 5. Elixir Medical Corporation
  • 6. Andramed GmbH
  • 7. QMD
  • 8. MicroPort Scientific Corporation
  • 9. Cook Medical LLC
  • 10. Becton, Dickinson and Company
  • 11. Integer Holdings Corporation
  • 12. W. L. Gore & Associates, Inc.
  • 13. SLTL Group
  • 14. Stryker Corporation
  • 15. Arterius Limited
  • 16. Meril Life Sciences Pvt. Ltd.
  • 17. BIOTRONIK SE & Co. KG
  • 18. Eurocor Tech GmbH
  • 19. Nano Therapeutics Pvt. Ltd.
  • 20. Scitech Medical Products SA
  • 21. Balton Sp. z o. o.
  • 22. Cardinal Health Inc.
  • 23. Boston Scientific Corporation
  • 24. KYOTO MEDICAL PLANNING Co., Ltd.
  • 25. Terumo Corporation
  • 26. B. Braun SE
  • 27. REVA Medical, LLC
  • 28. Medtronic PLC
  • 29. Rontis AG
  • 30. Veryan Medical Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦